BETA
Your AI-Trained Oncology Knowledge Connection!
Novel TKI Exhibits Durable Responses in HER2-Mutated NSCLC
BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.
Amivantamab Combo Shows Improved OS Trend Vs Osimertinib in EGFR+ NSCLC
Amivantamab/lazertinib also reduces the risk of second progression or death compared with osimertinib in the phase 3 MARIPOSA trial.
Omission of 5-FU From Combo Therapy May Improve Results in Advanced GI Cancers
The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.
Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation
Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.
Building the Foundation of a Successful Surgical Oncology Career
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy
Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.
Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer
Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.
Robot-Assisted Surgery May Be Standard Modality for Rectal Cancer Resection
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.
Subcutaneous Daratumumab Combo Improves MRD-Negative Status in NDMM
Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.
Data Support Increased Subcutaneous Rituximab Use in Non-Hodgkin Lymphoma
Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.
Liso-cel Shows Responses Across High-Risk Relapsed/Refractory CLL Subgroups
Earlier use of liso-cel may improve responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Minimally Invasive Surgery, Targeted Therapies Offer Options for CRC
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
FDA Approves Bortezomib Injection in Multiple Myeloma/MCL
A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.
FDA Approves FoundationOne Tests for Olaparib Combo in BRCA-Mutated mCRPC
Recent FDA approval of the companion diagnostics may help improve personalized treatment decision-making for patients with prostate cancer.
Early Neuro-Oncology Strategies May Hold Promise in Glioblastoma
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
TLX101/EBRT Shows Preliminary Tolerability, Efficacy in Glioblastoma
Phase 1 data may warrant further investigation of TLX101 plus external beam radiation therapy for patients with recurrent glioblastoma.
IBI363 Monotherapy Gets Fast Track Status for Advanced Melanoma
Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.
A Multidisciplinary Approach to Treating Resectable NSCLC
Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC
Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.
CB-012 Earns FDA Fast Track Status in R/R Acute Myeloid Leukemia
Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.
Cancer Rehabilitation Medicine: “Bridging the Gap” With Supportive Care
Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.
Niraparib May Show “Meaningful” Benefits in MGMT Unmethylated Glioblastoma
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Prior Encouraging Data Support Further Study of Niraparib in Glioblastoma
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma
“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.
Encorafenib Combo Earns European Approval in Advanced BRAF+ NSCLC
Data from the phase 2 PHAROS trial support the European Commission’s approval of encorafenib/binimetinib in NSCLC harboring a BRAF V600E mutation.
Adjuvant Chemotherapy May Have Survival Benefit in Stage III Locally Advanced NSCLC
Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.
Trials Evaluating Bispecific Antibodies in Earlier Therapy Lines Show Promise
Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.
1 Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients
Moving the Needle Forward in Cancer Rehabilitation
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups
Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.
![“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8b007a323176820eb0754e84186341fe7ca44ae4-350x350.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.")
